Download video

S3-04: Evaluating an HIV Vaccine efficacy vs. Counterfactual Placebo: immune Mediator Approach

347 views

IAS – the International AIDS Society

4 years ago

S3-04: Evaluating an HIV Vaccine efficacy vs. Counterfactual Placebo: immune Mediator Approach

S3-04: Evaluating an HIV Vaccine efficacy vs. Counterfactual Placebo: immune Mediator Approach

S3-04: Evaluating an HIV Vaccine efficacy vs. Counterfactual Placebo: immune Mediator Approach
28:50
S3-04: Evaluating an HIV Vaccine efficacy vs. Counterfactual Placebo: immune Mediator Approach
by IAS – the International AIDS Society
S1-06: Contingency Plans: Modelling effectiveness using counterfactuals (Deborah Donnell)
14:19
S1-06: Contingency Plans: Modelling effectiveness using counterfactuals (Deborah Donnell)
by IAS – the International AIDS Society
S1-08: Pre-randomization information can inform counterfactual estimation (David Glidden)
17:28
S1-08: Pre-randomization information can inform counterfactual estimation (David Glidden)
by IAS – the International AIDS Society
W26052107 Gene signature associating with HIV vaccine efficacy and antibody effector function
23:37
W26052107 Gene signature associating with HIV vaccine efficacy and antibody effector function
by IAS – the International AIDS Society
S2-05: A case study in using extra-trial data to infer placebo incidence (Mia Moore)
9:02
S2-05: A case study in using extra-trial data to infer placebo incidence (Mia Moore)
by IAS – the International AIDS Society
WEPL0104 - Toward an HIV Vaccine
28:05
WEPL0104 - Toward an HIV Vaccine
by IAC - the International AIDS Conference
HVTN 702 trial results - Glenda Gray, MBBCH, FCPaeds (SA), DSc
14:50
HVTN 702 trial results - Glenda Gray, MBBCH, FCPaeds (SA), DSc
by Academic Medical Education
Em busca de uma vacina contra o HIV
16:12
Em busca de uma vacina contra o HIV
by IAS – the International AIDS Society
W26052104 Mucosal Immune Activation in the Female Genital Tract in HVTN702 and RV144 (RV306).
14:40
W26052104 Mucosal Immune Activation in the Female Genital Tract in HVTN702 and RV144 (RV306).
by IAS – the International AIDS Society
Pathways to an HIV Vaccine - Mike keefer
44:02
Pathways to an HIV Vaccine - Mike keefer
by Alergia Imunopatologia FMUSP
First new HIV vaccine efficacy study in seven years has begun
4:36
First new HIV vaccine efficacy study in seven years has begun
by SABC News
Evaluation of the effect of ALFQA adjuvant on immunogenicity and efficacy of the V1-deleted
18:16
Evaluation of the effect of ALFQA adjuvant on immunogenicity and efficacy of the V1-deleted
by Innovinc Conferences
Webinar: Imbokodo Vaccine Trial Results and Implications for the Field—A Global Discussion
1:03:09
Webinar: Imbokodo Vaccine Trial Results and Implications for the Field—A Global Discussion
by HIVPxResearch
Daily Protein Intake
3:38
Daily Protein Intake
by Dr. Stacy Sims Official
Ad26 Mosaic Program—Janssen’s Maria Pau discusses preparations for the next efficacy trial
59:13
Ad26 Mosaic Program—Janssen’s Maria Pau discusses preparations for the next efficacy trial
by HIVPxResearch
W26052108 Workshop Final Remarks.
5:41
W26052108 Workshop Final Remarks.
by IAS – the International AIDS Society
W26052103 Behavioral Risk Analyses.
19:59
W26052103 Behavioral Risk Analyses.
by IAS – the International AIDS Society
2015 CFAR Scientific Retreat - Wilton Williams, Ph.D.
16:49
2015 CFAR Scientific Retreat - Wilton Williams, Ph.D.
by Duke CFAR
(August 1, 2023) Latest Update on Urgent Virus Outbreaks August 2023
1:00:16
(August 1, 2023) Latest Update on Urgent Virus Outbreaks August 2023
by IAS-USA
Q\&A Session 1: COVID \& HIV \& Women - Update on the Biomedical Advances
24:18
Q\&A Session 1: COVID \& HIV \& Women - Update on the Biomedical Advances
by Academic Medical Education